INVO Bioscience Eyes +20 U.S. Cities To Expand Rollout Of Advanced Infertility Treatment 'INVO Centers'

Rhea-AI Summary

INVO Bioscience (NASDAQ: INVO) updates its commercialization strategy for the INVOcell medical device, regaining full U.S. rights as of February 1, 2022. This initiative aims to address the unmet needs of the multi-billion dollar fertility market, where over 90% of couples seeking treatment are underserved. The INVOcell device enables intravaginal culture (IVC), allowing natural fertilization and embryo development at an affordable rate. Currently, the company operates three INVO Centers in Birmingham, AL, Atlanta, GA, and Monterey, Mexico, with plans to expand to 20 U.S. cities.

Positive

• Regained full U.S. commercialization rights for INVOcell, enhancing market access.
• Addresses significant unmet demand in the fertility market, with over 90% of couples lacking treatment.
• Plans to expand INVO Centers to 20 U.S. cities, increasing patient access.

Negative

• None.

SAN FRANCISCO, CA / ACCESSWIRE / February 9, 2022 / Today, the global fertility market is a multi-billion industry, yet remains severely underserved, with estimates suggesting more than 90% of couples in need of infertility treatment going without care. INVO Bioscience (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, believes that its INVOcell and the IVC procedure are well suited to address existing industry capacity challenges and provide an affordable and effective fertility option for patients in need. Intravaginal culture (IVC) is the process where a woman's body acts as a natural incubator. The first and only FDA-cleared, CE -marked medical device for IVC, INVOcell® (pictured below) holds the eggs and sperm within the woman's body during fertilization and early embryo development. Through its in vivo approach, INVOcell offers patients a more natural and intimate experience with comparable results at a lower cost.

Last week, INVO Bioscience, Inc. (NASDAQ:INVO) provided a commercialization update stating that effective February 1, 2022, INVO regained full U.S. commercialization rights to its INVOcell technology, enabling the Company to sell directly into existing IVF clinics, to expand the number of INVO Centers, clinics that focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution, free of any limitations, and to pursue its market expansion strategy focused on increasing access to care and democratizing fertility care for underserved patients. INVO Centers are believed to enjoy key advantages in the marketplace over current care options including: (a) lower startup costs - centers can be set up quickly and inexpensively within a relatively small footprint in urban, suburban, and rural areas, (b) higher capacity - centers are capable of performing far more cycles / embryologist, & (c) patent-protected device can be offered at an attractive cost to patients.

Currently, INVO Bioscience has three operating INVO Centers in Birmingham, AL, Atlanta, GA, & Monterey, Mexico. To learn more about INVO Bioscience's progress & plans, please visit the Vista Partners' website.

Company Contact
Steve Shum
Chief Executive Officer
978.878.9505
info@invobioscience.com

SOURCE: INVO Bioscience, Inc.

View source version on accesswire.com:
https://www.accesswire.com/687962/INVO-Bioscience-Eyes-20-US-Cities-To-Expand-Rollout-Of-Advanced-Infertility-Treatment-INVO-Centers

FAQ

What recent update did INVO Bioscience provide regarding INVOcell?

On February 1, 2022, INVO Bioscience regained full U.S. commercialization rights for its INVOcell technology.

How does INVOcell benefit patients seeking fertility treatment?

INVOcell allows for a more natural fertilization process at a lower cost, making fertility care more accessible.

What are the current locations of INVO Centers?

INVO Bioscience currently operates INVO Centers in Birmingham, AL, Atlanta, GA, and Monterey, Mexico.

What is the goal of expanding INVO Centers?

The goal is to increase access to affordable fertility care for underserved patients across 20 U.S. cities.